Donanemab

多奈单抗

Report date: 2026/05/25 20:02:40

Base Information

Drug NameDonanemab
Drug Alias NameN3pG-amyloid-betaN3pG-amyloid-beta Monoclonal Antibodydonanemab-azbtKisunla记能达 +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionBeta amyloid A4 protein scavengers
TargetsBeta amyloid A4 protein
Therapy Area/IndicationsCognitive DysfunctionCognition DisordersNeurocognitive Disorders +[15] 
Global Approved IndicationsCognitive DysfunctionAlzheimer DiseaseDementia
Approved Indications in ChinaCognitive DysfunctionAlzheimer DiseaseDementia
Original Approved Country/TerritoryUnited States
Original Approved Date2024/07/02
Country/TerritoryCzechiaCanadaUnited States +[15] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly Japan KkEli Lilly And CompanyEli Lilly Nederland BV
Inactive CompaniesLilly France SasLilly Suzhou Pharmaceutical Co Ltd
Active IndicationsCognitive DysfunctionCognition DisordersNeurocognitive Disorders +[13] 
Inactive IndicationsMental DisordersNervous System Diseases

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG